December 6, 2011 - 10:30 AM EST Print Email Article Font Down Font Up Charts AQLV 0.0046 0.0035 Today 5d 1m 3m 1y 5y 10y
AquaLiv Technologies' Subsidiary, AquaLiv, Inc. Receives Conditional Commitment Letter Offering $50 Million In Working Capital
SEATTLE, Dec. 6, 2011 /PRNewswire/ -- AquaLiv Technologies, Inc. (OTCBB: AQLV) subsidiary, AquaLiv, Inc., announces it has received a Conditional Commitment Letter from an undisclosed investment group intending to provide the company with $50 million USD in working capital.
According to the company, all of the terms and fees of the financing have been agreed upon. The group may provide the majority of the round as debt, but may elect to take a yet unknown portion as a direct equity contribution. The company expects to receive the first tranche of funding after the first of the year. AquaLiv has been discussing its future plans with the investment group since June, during which time the group was performing their due diligence.
"Due diligence takes time. There is no scientific precedent for our technological capability and without a fair amount of education by us, even most scientists won't understand it," stated AquaLiv, Inc. CEO Craig Hoffman. "Outside of a simple scientific validation performed by a University of Washington scientist last year, our strategy was to allow the marketplace to validate our technology. And, we've gone to great lengths to seed various industries with our products, even though we've really had insufficient capital and manpower to do so - up until now that is."
"We can put any serious investment group in touch with numerous persons outside of our company who are delighted to be working with us and our technology, including: an organic rice farm that has increased its yield by 30%, HIV/AIDS patients with vastly improved quality of life, a commercial bakery in Tokyo that is able to reduce the amount of yeast required to raise dough resulting in a sweeter tasting product with a longer shelf life, a prominent health club that is able to reduce the amount of chlorine required to eliminate bacteria in their pool and spa, and the list goes on. We've eliminated the risk of whether or not we can bring products to market. We've demonstrated success. Now it's time to scale."
"It isn't easy raising capital in this economy and a lot of strong companies are competing for what capital is available," stated Bill Wright, CEO of AquaLiv Technologies, Inc. "The simple fact that this group has worked closely with AquaLiv for five months and intends to provide $50 million in funding is a glowing testament. AquaLiv clearly demonstrated the capabilities of their technology and the viability of their business plan."
"We have signed a non-disclosure agreement, so we are unable to name the group just yet," stated Mr. Hoffman. "However, we have been working with this group for months and are excited to finally make this announcement."
Mr. Wright continued, "Based on the selection of two product lines alone, the AquaLiv business plan represents over $1 billion in projected sales over the first six years. As we have stated before, this is not a sprint, but a marathon. With the technology and the endless applications of the science before us, AquaLiv plans on being a household name for generations to come."
"Standby for fireworks," added Mr. Hoffman. "We're moving the rocket to the launchpad."
The company released its first agriculture product, AgSmart™ Rice, earlier this year, and is close to releasing their potato solution. AgSmart™ products increase crop yields without chemicals or genetic engineering and are organic standards compliant. The company is also preparing for an upcoming clinical trial with their NatuRx™ HIV/AIDS treatment.
AquaLiv Technologies, Inc., through its subsidiary, AquaLiv, Inc., offers unique solutions and for a variety of industries.
AquaLiv, Inc. is a life sciences research and development company creating novel products for numerous industries. The company's patented technology alters the behavior of organisms, including plants and humans, without chemical interaction. From increased crop yields to drug-free medicine, AquaLiv is providing innovative, ingredient-free solutions to the world's largest problems. To learn more about AquaLiv, please visit:www.aqualiv.net.
Safe Harbor: Statements contained in this news release, other than those identifying historical facts, constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and the Safe Harbor provisions as contained in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relating to the Company's future expectations, including but not limited to revenues and earnings, technology efficacy, strategies and plans, are subject to safe harbors protection. Actual Company results and performance may be materially different from any future results, performance, strategies, plans, or achievements that may be expressed or implied by any such forward-looking statements. The Company disclaims any obligation to update or revise any forward-looking statements.
October 31, 2011 - 2:09 PM EDT Print Email Article Font Down Font Up Charts AQLV 0.0054 0.0043 Today 5d 1m 3m 1y 5y 10y
AquaLiv Technologies Subsidiary AquaLiv, Inc. Discusses Registration In Kenya Concerning Its HIV/AIDS Treatment
SEATTLE, Oct. 31, 2011 /PRNewswire/ -- AquaLiv Technologies (OTCBB: AQLV) subsidiary, AquaLiv, Inc., discusses alternative medicine registration in Kenya for their NatuRx™ HIV/AIDS treatment.
The company previously announced that Kenyan officials recommend they register NatuRx™ HIV/AIDS as an alternative medicine treatment and that approval could be granted within 30-60 days.
"The process isn't quite as simple as it was explained to us," stated AquaLiv CEO, Craig Hoffman. "It isn't just the treatment that is being registered. Registration also requires completed retail packaging and inspection of a manufacturing facility that complies with cGMP (Current Good Manufacturing Practices) regulation. We wanted to simply get approval for the treatment, but that just isn't possible without the manufacturing component in place."
Mr. Hoffman continued, "We are looking for a manufacturing partner that could eventually supply the treatment to all African countries and we have identified some candidates in both Kenya and India. The big question for us right now is do we sign on with a partner capable of manufacturing our treatment as a liquid solution, as we do now in our laboratory, or should we wait until we have modified the treatment to be delivered in tablet form. We're closer than ever to being able to deliver all NatuRx™ treatments in tablet form and we think we will know definitively before the end of our planned clinical trial, which is when we would actually begin sales of the product."
The company further explained that tablets are more economical to distribute and will require fewer manufacturing partners overall.
"We're confident we will have the manufacturing issues worked out before the end of the trial," added Bill Wright, CEO of AquaLiv Technologies. "However, we communicated to our investors that an alternative medicine registration could be granted around this time and felt it was important to give investors an update."
Based on AquaLiv's patented BioT™ Bioinformation Technology, NatuRx™ formulations utilize novel wave-based information composites in lieu of molecules for treatment.